EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials

Carly de Faria Coelho iD, Rodolfo P Vieira iD, Osvaldo Soares Araújo-Junior iD, Pedro Sardinha Leonardo Lopes-Martins iD, Larissa Gomes Dos Santos iD, Lucas Danilo Dias, Alberto Souza de Sá Filho iD, Patrícia Sardinha Leonardo, Sandro Dutra E Silva, Rodrigo Alvaro Brandão Lopes-Martins iD

Life · 25.10.2024 · 14 (11) · 1373

DOI: 10.3390/life14111373 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 25.10.2024. Verfasst von Carly de Faria Coelho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biophotonics and Experimental Therapeutics-LABITEX, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis …. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Goiás Research Foundation (FAPEG), National Council for Scientific and Techno-logical Development (CNPq).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms “cannabidiol” and “anxiety”. Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD’s potential efficacy across different conditions.

Schlagwörter

Stichwörter der Autor:innen

RCTanxietycannabidiolneuropsychological effectspsychiatry

Autor:innen und Institutionen

  • Laboratory of Biophotonics and Experimental Therapeutics-LABITEX, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
  • Laboratory of Exercise Immunology, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
  • Laboratory of Applied Neurosciences, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
  • Laboratory of New Materials, Post-Graduate Program in Pharmaceutical Sciences, Pharmacology and Therapeutics, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
  • Laboratory of Health Technologies-LATES, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
  • Laboratory of Natural History of Cerrado, Post-Graduate Program in Pharmaceutical Sciences, Pharmacology and Therapeutics, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO…

ORCID-Profile: Carly de Faria Coelho, Rodolfo P Vieira, Osvaldo Soares Araújo-Junior, Pedro Sardinha Leonardo Lopes-Martins, Larissa Gomes Dos Santos, Alberto Souza de Sá Filho, Rodrigo Alvaro Brandão Lopes-Martins

Förderung

  • Goiás Research Foundation (FAPEG)
  • National Council for Scientific and Techno-logical Development (CNPq)

Zitieren

APA

Coelho, C. F., Vieira, R. P., Araújo-Junior, O. S., Lopes-Martins, P. S. L., Dos Santos, L. G., Dias, L. D., Filho, A. S. S., Leonardo, P. S., Silva, S. D. E., & Lopes-Martins, R. A. B. (2024). The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials. Life, 14(11), 1373. https://doi.org/10.3390/life14111373

Vancouver

Coelho CF, Vieira RP, Araújo-Junior OS, Lopes-Martins PSL, Dos Santos LG, Dias LD, et al. The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials. Life. 2024;14(11):1373. doi:10.3390/life14111373

BibTeX
@article{Coelho2024,
  author = {Coelho, Carly de Faria and Vieira, Rodolfo P and Araújo-Junior, Osvaldo Soares and Lopes-Martins, Pedro Sardinha Leonardo and Dos Santos, Larissa Gomes and Dias, Lucas Danilo and Filho, Alberto Souza de Sá and Leonardo, Patrícia Sardinha and Silva, Sandro Dutra E and Lopes-Martins, Rodrigo Alvaro Brandão},
  title = {The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials},
  journal = {Life},
  year = {2024},
  volume = {14},
  number = {11},
  pages = {1373},
  doi = {10.3390/life14111373}
}
Kostenlos starten →